Catalent to provide fill-finish for Moderna's COVID-19 vaccine

By The Science Advisory Board staff writers

June 25, 2020 -- Catalent will collaborate with Moderna for large-scale commercial fill-finish manufacturing of Moderna's messenger RNA (mRNA)-based COVID-19 vaccine candidate, mRNA-1273, at Catalent's biologics facility in Bloomington, IN.

Under the agreement, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for around-the-clock manufacturing operations to support the production of an initial 100 million doses of the vaccine candidate. The Bloomington biologics facility will provide vial filling using barrier isolator technology within the 875,000-sq-ft space. Production of these doses are intended to supply the U.S. market starting in the third quarter of 2020.

Catalent will also provide clinical supply services from its facilities in Philadelphia, PA. This includes packaging and labeling, storage, and distribution services to support Moderna's phase III clinical trial.

Moderna moves COVID-19 vaccine to late-stage clinical trial
Moderna has finalized phase III clinical study protocols for its mRNA-1273 COVID-19 vaccine candidate in coordination with the U.S. Food and Drug Administration...
CordenPharma to provide excipients for Moderna's vaccine candidate
A supplier of active pharmaceutical ingredients, CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale...
Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...
Catalent completes acquisition of MaSTherCell
Catalent announced on February 11 that it has completed its acquisition of MaSTherCell Global, improving Catalent's position in the field of advanced...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter